The Benefits and Costs of Treating Obesity among Adults in Commercial Insurance Plans
Year: 2026
Type: other
Abstract: Objective: To evaluate the clinical, economic, and social benefits and costs of evidence-based obesity treatment among commercially insured adults. Research Design and Methods: Using a Markov-based microsimulation model, we projected 5-year clinical and economic outcomes of intensive lifestyle management, obesity medications, and metabolic/bariatric surgery, drawing on data from clinical trials, national surveys, and economic studies. Results: This analysis focuses on 47.3 million commercially insured adults with obesity who lack access to treatment through existing clinical pathways. Over five years, cumulative medical savings per person range from $2,908 for lifestyle intervention to $2,450–$7,304 for obesity medications and $12,001 for surgery among adults without pre-existing diabetes or cardiovascular disease. At the population level, access to treatment would yield five-year benefits of $9.7 billion in medical savings, $25.8 billion in productivity gains, $38.8 billion in quality-of-life value, and $29.6 billion in mortality reduction benefits, requiring $44.7 billion in total investment. Combined benefits produced net social value of $59.1 billion with a $2.35 return per dollar invested and positive returns as early as the second year. Conclusions: Obesity treatment generates substantial social benefits through improved health outcomes and productivity gains. Medical and disability cost savings and workplace productivity improvements combined recover 81% of treatment investment. Employees effectively finance coverage through premiums and reduced wages, and comprehensive benefit design that includes health outcomes and quality-of-life improvements more accurately reflects societal treatment value. Coverage decisions based solely on employer economic returns underestimate the full societal value of expanding coverage. Article Highlights · Why did we undertake this study? Most commercially insured adults with obesity lack access to evidence-based treatment, yet the economic and social value of expanding coverage remains poorly characterized. · What is the specific question we wanted to answer? What are the clinical, economic, and social benefits and costs of obesity treatment among commercially insured adults? · What did we find? Per-person medical savings over five years range from $2,908 for lifestyle intervention to $2,450–$7,304 for obesity medications and $12,001 for surgery, generating $59.1 billion in net social value with a $2.35 return per dollar invested. · What are the implications? Because employees finance coverage through premiums and reduced wages, benefit designs incorporating quality-of-life improvements and productivity gains alongside medical cost savings more accurately reflect the full value of obesity treatment.
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7163749667